News

The FDA has advised Seelos that it may proceed with the proposed clinical trial SLS-005-201 for Mucopolysaccharidosis type III (Sanfilippo syndrome). “We are very pleased to have received

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the

Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based

The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient

Dr Hal Barron, Chief Scientific Officer and President R&D, GSK said, “Around 3.5 million patients in Japan have anaemia associated with renal disease which can result in weakness

The new facility is believed to support the company’s continuing investment in gene therapy research and development similar to its research and development sites in Chapel Hill and

As per the terms of the deal, Bayer will receive $5.3bn (£4.37bn) in cash and will be issued $2.3bn (£1.9bn) worth shares in the US-based Elanco Animal Health.

Proceeds from the financing will be used to progress GB-102, the company’s lead asset, into both a phase 2b clinical study (the ALTISSIMO study) in wet AMD as

The FDA has granted Priority Review of the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 19, 2020. The submission was